Eli Lilly (LLY): Rep. Gilbert Ray Cisneros Jr. (CA31) disclosed a purchase $1K–$15K
Rep. Gilbert Ray Cisneros Jr. (CA31) disclosed a purchase of Eli Lilly in the $1K–$15K range.
- $1,001–$15,000
- Reported range · official band, not an exact amount
- 24 days
- Disclosure lag
- Traded
- Apr 14, 2026
- Disclosed
- May 8, 2026
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Dec 2, 2025CongressDisclosed sale of LLY — reported range $1,001 - $15,000
- Jan 2, 2026CongressDisclosed purchase of LLY — reported range $1,001 - $15,000
- Feb 9, 2026CongressDisclosed sale of LLY — reported range $1,001 - $15,000
- Feb 13, 2026CongressDisclosed sale of LLY — reported range $1,001 - $15,000
- Feb 26, 2026CongressDisclosed purchase of LLY — reported range $1,001 - $15,000
- Mar 13, 2026CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
- Mar 26, 20265% stakeThe Vanguard Group reported a passive stake (13G)
- Mar 27, 2026CongressDisclosed sale of LLY — reported range $1,001 - $15,000
- Apr 1, 2026FDAFDA drug approval: Foundayo
- Apr 2, 2026Congress · 1 personMembers of Congress: 2 purchases
- Apr 8, 2026CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
- Apr 14, 2026 · this disclosureCongressDisclosed purchase of LLY — reported range $1,001 - $15,000
What came next
- Apr 20, 20265% stakeLILLY ENDOWMENT, INC. reported a passive stake (13G) of 9.7%
- Apr 30, 2026Company filing · Form 8-K · ResultsReported its results
- May 1, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 6.5%
- May 6, 2026Insider · 1 personInsiders: 2 sales (~$15.8M)
- May 15, 2026Federal contract · $52K obligatedDepartment of Veterans Affairs awarded Eli Lilly: $52K obligated to date
- Jun 9, 2026FDAFDA drug approval: Ebglyss
- Jun 10, 2026Insider · Their largest sale since 2022Officer sold ~$2.88M of LLY shares in the open market
- Jun 10, 2026Congress · 1 personMembers of Congress: 2 purchases
- Jul 1, 2026CongressDisclosed sale of LLY — reported range $1,001 - $15,000
- Jul 10, 2026CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
- Jul 13, 2026FDAFDA drug approval: Verzenio
- Jul 14, 2026FDAFDA drug approval: Retevmo
- Jul 14, 2026FDAFDA drug approval: Retevmo
- Jul 23, 20265% stakeLILLY ENDOWMENT, INC. reported a passive stake (13G) of 9.6%
- Aug 5, 2026Company filing · Form 8-K · ResultsReported its results
- Aug 7, 2026InsiderOfficer sold ~$5.95M of LLY shares in the open market
- Aug 10, 2026Insider · Their largest sale since 2014Officer sold ~$2.37M of LLY shares in the open market
How to read House Clerk periodic transaction report
The STOCK Act is a 2012 US law that requires members of Congress, and some senior staff, to publicly report their stock trades, and those of their spouse and dependent children, within 45 days.
Full guide: What is the STOCK Act?
What else is on file for Eli Lilly
For Eli Lilly, OQRO holds 4 insider filings (SEC Form 4 or Form 144), 3 Congress trade reports, 5 fund holdings reports (13F) and 1 federal contract award dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its LLY page.
Other recent filings by Rep. Gilbert Ray Cisneros Jr. (CA31)
- House Clerk periodic transaction report at Alexandria Real Estate Equities (ARE)Nov 10, 2026
- House Clerk periodic transaction report at Alliant Energy (LNT)Nov 10, 2026
- House Clerk periodic transaction report at AppLovin (APP)Nov 10, 2026
- House Clerk periodic transaction report at AppLovin (APP)Nov 10, 2026
- House Clerk periodic transaction report at Argenx (ARGX)Nov 10, 2026
The full history of Rep. Gilbert Ray Cisneros Jr. (CA31) is on the profile page.
How this filing works
Explore the data
Common questions
Which member of Congress traded Eli Lilly (LLY) stock, and how much?
Rep. Gilbert Ray Cisneros Jr. (CA31) disclosed a purchase of Eli Lilly in the $1K–$15K range. Reported range, not an exact amount.
When did it happen, and when was it made public?
Traded: Apr 14, 2026. Disclosed: May 8, 2026. That is 24 days between the two dates.
Why is the amount a range and not an exact figure?
Members of Congress report each trade in a bracket set by law ($1,001 to $15,000, $15,001 to $50,000, and so on), never an exact amount. OQRO keeps the bracket as filed and does not estimate a figure inside it.
Where does this information come from?
From the House Clerk periodic transaction report, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Eli Lilly recently?
For Eli Lilly, OQRO holds 4 insider filings (SEC Form 4 or Form 144), 3 Congress trade reports, 5 fund holdings reports (13F) and 1 federal contract award dated in the last 90 days. They are listed on the LLY page.
Does this mean LLY stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Eli Lilly
- SEC Form 13F-HRNov 16, 2026
- SEC Form 13F-HRNov 16, 2026
- SEC Form 13F-HRNov 13, 2026
- House Clerk periodic transaction reportNov 12, 2026
- House Clerk periodic transaction reportNov 12, 2026
- House Clerk periodic transaction reportNov 10, 2026
Everything OQRO holds on this company is on its LLY page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
